Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Change in Accured Expenses (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Change in Accured Expenses for 2 consecutive years, with $5000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Change in Accured Expenses rose 100.22% year-over-year to $5000.0, compared with a TTM value of $2000.0 through Dec 2024, up 100.09%, and an annual FY2024 reading of $2000.0, up 100.09% over the prior year.
  • Change in Accured Expenses was $5000.0 for Q4 2024 at Oramed Pharmaceuticals, down from $663000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $663000.0 in Q2 2024 and bottomed at -$2.2 million in Q4 2023.